Cosmos Health Q2 Loss Widens 115% as Going Concern Doubt Persists
COSM sits 27% above its 52-week low of $0.162 on light trading volume (0.2× avg).
Summary
Cosmos Health's Q2 loss more than doubled to $6.09M, with going concern doubt reiterated and material internal control weaknesses disclosed. Heavy dilution continued via convertible note conversions.
Key Events · Earnings and Guidance · COSM
-
Q2 Net Loss Widens 115%
Net loss of $6.09M for Q2 2026 vs $2.83M in Q2 2025, driven by $2.38M non-cash loss on convertible note fair value and $404K loss on digital assets.
-
Going Concern Doubt Reiterated
Management states substantial doubt about ability to continue as a going concern, with $1.8M unrestricted cash and $34.8M current liabilities as of June 30, 2026.
-
Material Weaknesses in Internal Controls
Disclosure controls and procedures deemed ineffective due to inadequate segregation of duties and IT general control deficiencies.
-
Heavy Dilution from Convertible Notes
22.9M shares issued on conversion of August 2025 Note during H1 2026, with 20.5M more issued after quarter-end, leaving only $82.5K principal outstanding.
Analysis · COSM · Trade & Services
A Q2 net loss of $6.09 million—more than double the prior-year period—was driven by non-cash charges from convertible note fair-value adjustments and digital asset losses. The company reiterated substantial doubt about its ability to continue as a going concern, with only $1.8 million in unrestricted cash against $34.8 million in current liabilities. Management also disclosed material weaknesses in internal controls and continued heavy dilution, issuing 22.9 million shares on convertible note conversions during the quarter.
At the time of this filing, COSM was trading at $0.20 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.16 to $1.32. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.